IU receives $2M gift supporting lung, pancreatic cancer research

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

A dual-threshold model for measuring the pancreatic tumor marker serum carbohydrate antigen 19-9 (CA19-9) identified patients with pancreatic cancer who had high-risk disease despite having low CA19-9 levels because of a genetic variation that impairs their ability to produce this biomarker.

May 29, 2026

Vol.52 No.21

Drugs & Targets

FDA grants Orphan Drug designation to oxaliplatin delivered via RenovoCath catheter for pancreatic cancer

RenovoRx Inc. received an Orphan Drug Designation of oxaliplatin for the treatment of pancreatic cancer delivered via RenovoCath device.

May 29, 2026

Vol.52 No.21

Clinical Roundup

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

A head-to-head comparison of five leading treatments for anaplastic lymphoma kinase-positive non-small cell lung cancer could help oncologists fine-tune first-line TKI selection beyond what’s been seen in clinical trials alone, according to a study conducted by a team of researchers from the Keck School of Medicine of USC, the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences and the USC Shaeffer Center for Health Policy & Economics have conducted.

May 22, 2026

Vol.52 No.20

Clinical Roundup

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in options over recent decades that have created meaningful improvements in lifespan and quality of life for many patients.

May 15, 2026

Vol.52 No.19

Clinical Roundup

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

Scientists at Oregon Health & Science University have developed a technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer. The technique offers a new way to detect early signs of pancreatic cancer—a particularly deadly type of cancer because it isn’t detected until it’s progressed to later stages that are difficult to treat effectively. The new method would involve a simple blood draw among people who are considered higher risk due to family history or other factors.

May 08, 2026

Vol.52 No.18

Drugs & Targets

FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib

FDA has issued a “safe to proceed” letter to Revolution Medicines, allowing the sponsor to initiate an expanded access treatment protocol for its experimental pancreatic cancer drug, daraxonrasib, a RAS inhibitor.

May 08, 2026

Vol.52 No.18

By Claire Marie Porter

IU receives $2M gift supporting lung, pancreatic cancer research

YOU MAY BE INTERESTED IN

Adding a lower cutoff value for CA19-9 may identify additional high-risk cases of pancreatic cancer

FDA grants Orphan Drug designation to oxaliplatin delivered via RenovoCath catheter for pancreatic cancer

USC comparison study of leading targeted therapies for ALK+ lung cancer could lead to better treatment decisions

Despite breakthroughs, many go without treatment for metastatic lung cancer, MUSC study finds

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

FDA permits expanded access for investigational pancreatic cancer drug daraxonrasib

Renew today!

Subscriber content

Never miss an issue!

Login